Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor

Basit Öğe Kaydı
dc.contributor.authorCetin, Bulent
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorBerk, Veli
dc.contributor.authorTufan, Gulnihal
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorOzkan, Metin
dc.date.accessioned2024-04-24T17:08:06Z
dc.date.available2024-04-24T17:08:06Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractSurgical resection of asymptomatic primary colorectal cancer in patients presenting with synchronous unresectable metastatic disease is controversial. Concerns and controversies remain over combining cytotoxic chemotherapy with bevacizumab in this patient population. We identified medical records of 99 patients with synchronous metastatic primary colorectal cancer who received chemotherapy with bevacizumab as their initial treatment. The incidence of subsequent use of surgery and surgical outcomes were recorded. Patients were also assessed for overall survival. Patients who received bevacizumab-containing chemotherapy for synchronous metastatic primary colorectal cancer were divided into the non-surgery and surgery groups according to the resection status of their asymptomatic primary tumor. In the non-surgery group, two patients (4.4) underwent additional surgery, while three patients (5.7) required surgery for rectovesical fistula in the surgery group. The median overall survival was 17 months for the non-surgery group (95 CI: 10.623.3 months) and 23 months for the surgery group (95 CI: 21.324.6 months; P 0.322). This study utilizing chemotherapy with bevacizumab did not result in an increased rate of morbidity related to the unresected primary tumor. Survival is not compromised by leaving the primary colon tumor intact.en_US
dc.identifier.doi10.1093/jjco/hys175
dc.identifier.endpage32en_US
dc.identifier.issn0368-2811
dc.identifier.issn1465-3621
dc.identifier.issue1en_US
dc.identifier.pmid23107836
dc.identifier.scopus2-s2.0-84871749730
dc.identifier.scopusqualityQ2
dc.identifier.startpage28en_US
dc.identifier.urihttps://doi.org/10.1093/jjco/hys175
dc.identifier.urihttps://hdl.handle.net/11468/17204
dc.identifier.volume43en_US
dc.identifier.wosWOS:000312890700006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofJapanese Journal of Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectIntact Primary Tumoren_US
dc.subjectBevacizumaben_US
dc.subjectChemotherapyen_US
dc.titleBevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumoren_US
dc.titleBevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu